The GPATCH3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT-29 human colorectal adenocarcinoma line, featuring targeted disruption of the GPATCH3 gene. This heterogeneous pool comprises cells with various loss-of-function alleles at the GPATCH3 locus, generated through Cas9-mediated double-strand break repair by non-homologous end joining. The polyclonal format preserves the biological variability of the parental line while ensuring depletion of GPATCH3 protein, delivering a robust tool for functional genomics studies without the necessity of isolating single-cell clones. The cells are suitable for a broad range of molecular and cellular assays focused on RNA biology and cancer phenotypes.
The HT-29 cell line originates from a primary colorectal adenocarcinoma in a 44-year-old female and is one of the most extensively employed models in colorectal cancer research. HT-29 cells grow as adherent epithelial monolayers, possess the capacity to form tight junctions, and can differentiate toward an enterocytic phenotype under appropriate conditions. These features render the line advantageous for investigating intestinal barrier integrity, drug absorption, and transepithelial transport. Genomically, HT-29 harbors an activating BRAF V600E mutation and mutant TP53, which drive constitutive MAPK pathway signaling and impair tumor suppressor responses, thereby providing a genetically defined backdrop for mechanistic studies of oncogenic pathways.
GPATCH3 encodes a predicted RNA-binding protein distinguished by a G-patch domain, a glycine-rich motif typically found in regulators of RNA splicing and processing. Although its precise cellular role has not been experimentally established, GPATCH3 is hypothesized to function in pre-mRNA splicing and may associate with components of the spliceosome. Putative interacting factors include the RNA helicase DHX15, a spliceosome?associated protein involved in lariat intron turnover, and SKIV2L2, a helicase linked to the RNA exosome that participates in RNA surveillance. Nevertheless, its knockout is predicted to alter splicing isoform repertoires, potentially impacting gene expression programs governing cell cycle, apoptosis, and stress responses.
Contextualized within colorectal adenocarcinoma, the GPATCH3 knockout in HT-29 cells provides a pertinent model to explore RNA processing dysregulation in tumor biology. Aberrant splicing is an established hallmark of many cancers, contributing to oncogenic transformation, metastasis, and drug resistance. By perturbing a putative splicing?regulatory protein in an epithelial tumor cell line, researchers can probe how splicing factor loss influences malignant properties such as proliferation, motility, and chemosensitivity. Furthermore, the ability of HT-29 to form polarized, tight-junction?sealed monolayers allows investigation of whether GPATCH3 depletion compromises barrier function or promotes epithelial?mesenchymal transition, both of which are clinically relevant processes in colorectal cancer progression.
The GPATCH3 Knockout HT29 Polyclonal Cells support a range of experimental approaches. Transcriptome?wide RNA?sequencing can reveal global splicing alterations and differentially expressed genes upon GPATCH3 disruption, with subsequent validation by RT?qPCR and Western blotting. Proliferation can be quantified via MTT or colony?forming assays, migration assessed through transwell or wound?healing methods, and drug sensitivity profiled by dose?response curves. Interaction partners are readily identifiable through co?immunoprecipitation for protein?protein contacts and RNA immunoprecipitation for RNA?binding targets. Thus, these cells provide a flexible tool for both targeted hypothesis testing and discovery-driven analyses. For technical assistance or purchase inquiries, please contact Ascent Research.
